suggested that posttransplantation mutations on hematopoiesis–associated genes DNMT3A, TET2, and ASXL1 had no prognostic impact in patients with AML [24], dynamic evaluation of pre‐ and post‐transplant ASXL1 should be made to fully explore the prognostic effect of ASXL1 burden on allo‐HSCT. This evidence concerns the gene TET2 and acute myeloid leukemia.